Condition: Primary Central Nervous System Lymphoma (PCNSL) · Secondary Central Nervous System Lymphoma (SCNSL) · Sponsor: The First Affiliated Hospital with Nanjing Medical University
This is a multicenter, open-label, single-arm, prospective clinical study of PD-1 inhibitor combined with rituximab, methotrexate, and orelabrutinib (PD-1i+RMO) in the treatment of newly diagnosed primary central nervous system lymphoma (ND-PCNSL) and secondary central nervous system lymphoma (SCNSL). The primary endpoint is 1-year progression-free survival (PFS).
This description comes directly from the study's public registry record.
Lei Fan · +8613813976136 · fanlei3014@126.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital with Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07410520